reading glasses. Mumbai-based Entod Pharmaceuticals announced the final approval for PresVu eye drops, with plans to launch the product in the domestic market in the first week of October.
PresVu is the first eye drop in India specifically designed to address presbyopia, a common age-related vision problem that typically affects individuals over 40. The approval followed a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
«This approval from the DCGI is a significant milestone in our mission to revolutionize eye care in India. PresVu is more than just a product; it's a solution that can enhance the lives of millions by providing them with greater visual independence,» said Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, as quoted by news agency PTI.
Presbyopia affects between 1.09 and 1.8 billion people worldwide, making it a widespread issue as people age, leading to a decreased ability to focus on nearby objects. Entod Pharmaceuticals aims to address this issue not only in India but also in emerging markets such as Africa and Southeast Asia.
Discussing the company’s future plans, Masurkar stated, «Most exports to the US are low-cost generics. We aim to change that by focusing on innovation and becoming a global leader in new developments, which we can then out-license to other countries. This is our future
Read more on economictimes.indiatimes.com